Printer Friendly

COMPANY INFORMATION
IBEX Technologies Inc. 5485 rue Paré Montréal, QC H4P 1P7 Tel: (514) 344-4004 Fax: (514) 344-8827 Contact Name Paul Baehr Industry Biotechnology		Key Executives Paul Baehr, CEO Nancy Bisson, v-p, fin. Develops therapeutics and diagnostics for the management of cancer and arthritis. Also markets a series of glycobiology enzymes (heparinases and chondroitinases).
FP ADVISOR COVERAGE IBEX Technologies Inc. • FP Corporate Surveys • FP Directory of Directors • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 4/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/IBT $0.25 $0.35 $0.06 n.a. n.a. n.a. 0.77 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 7,660 6.20 $0.04 Apr. 30/09 316.67% 5.98% -7.29% $6,176
ANNUAL FINANCIALS Periods ended: 12m July 31/08 12m July 31/07 12m July 31/06 $000s $000s $000s Operating revenue 2,327 2,024 2,092 Net income 348 (7,410) (2,880) Total assets 2,527 2,552 10,100 $ $ $ Earnings per share* 0.01 (0.32) (0.12) % % % Return on equity 18.42 (140.04) (28.00)   * Common

COMPANY NEWS

Results for 'IBEX Technologies Inc.' from past 30 days: No hits. (Links are to articles.)